The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

Treatment responses to Xalkori were not affected by PD-L1 expression in patients with advanced non-small cell lung cancer and ROS1 rearrangements. Patients with advanced non-small cell lung cancer ...

The efficacy of molecule-matched treatment on hyperprogressive disease after immunotherapy: A retrospective study from the Molecular Tumor Board registry. This is an ASCO Meeting Abstract from the ...

Effect of low-dose rapamycin on the therapeutic response to radio-immunotherapy in hepatocellular carcinoma. Multi-omics analysis of PD-1 inhibitor combination in neoadjuvant treatment of pMMR/MSS ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...